Zacks analysts retain neutral stance on Sanofi
Analysts at USA-based Zacks Equity Research say they are reaffirming their Neutral stance on Sanofi (Euronext: SAN) with a target price of $38.00, noting that the French pharma giant is one of the largest biopharmaceutical companies in the world and recorded 2010 sales of approximately $41.4 billion.
Sanofi has a diversified product portfolio with a strong presence in several therapeutic areas including cardiovascular diseases, diabetes, oncology and central nervous system disorders. In fact, they noted, Sanofi has perhaps one of the strongest cardiovascular franchises amongst all large-cap pharmaceuticals. Additionally, the company boasts strong vaccine operations.
Facing generic competition
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze